19. EARNINGS PER SHARE

We compute basic earnings per share by dividing net income attributable to Core Laboratories Inc. by the number of weighted average common shares outstanding during the period. Diluted earnings per share includes the incremental effect of contingently issuable shares from performance and restricted stock awards, as determined using the treasury stock method.

The following table summarizes the calculation of weighted average common shares outstanding used in the computation of basic and diluted earnings per share (in thousands):

 

 

For the Years Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Weighted average common shares outstanding - basic

 

 

46,427

 

 

 

46,897

 

 

 

46,683

 

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

Restricted shares

 

 

41

 

 

 

52

 

 

 

97

 

Performance shares

 

 

560

 

 

 

736

 

 

 

743

 

Weighted average common shares outstanding - diluted

 

 

47,028

 

 

 

47,685

 

 

 

47,523

 

Historical Timeline

Fiscal YearFiled
2025Mar 23, 2026Showing above
2024Feb 13, 2025

About Earnings Per Share Disclosures

The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.

Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.